Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of OT-502 (Dexycu) for Inflammation after Cataract Surgery
NCT06429306Phase 3Completed
- Sponsor
- Ocumension Biotech
- Start
- Aug 2022
- Primary completion
- Nov 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of dexamethasone in post-operative inflammation, sponsored by Ocumension Biotech. Started Aug 2022; status: completed.
02
Drugs
dexamethasone
03
Conditions
post-operative inflammation
Beyond the preview
Go deeper on NCT06429306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06429306.